Preferred Label : BTK Inhibitor ABBV-992;
NCIt definition : An orally bioavailable and irreversible covalent inhibitor of Bruton's tyrosine kinase
(BTK), with potential antineoplastic activity. Upon oral administration, BTK inhibitor
ABBV-992 targets, binds to and inhibits the activity of BTK and prevents the activation
of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell
activation and BTK-mediated activation of downstream survival pathways. This leads
to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member
of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed
in B-cell malignancies. It plays an important role in B-lymphocyte development, activation,
signaling, proliferation and survival.;
Molecule name : ABBV-992; ABBV 992;
NCI Metathesaurus CUI : CL1663034;
Origin ID : C180412;
UMLS CUI : C5556350;
Semantic type(s)
- concept_is_in_subset
- has_target
